Clinical Trial Update: A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial compares HLX15-SC with DARZALEX FASPRO in combination with lenalidomide and dexamethasone for transplant-ineligible newly diagnosed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))
• DEXAMETHASONE (Dexamethasone)
• HLX15-SC (HLX15-SC)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Multiple Myeloma (MM) | Phase 1 | Status: NOT_YET_RECRUITING